The subfamily of WNK (with no K ¼ lysine) protein kinases has four human members and germline mutations in the WNK1 and WNK4 genes were recently found to cause pseudohypoaldosteronism type II, a familial hypertension disease. Here, we describe cloning and functional analysis of a further WNK member, human WNK3. Endogenous WNK3 protein is an active protein kinase when immunoprecipitated from cells and its overexpression increases the survival of HeLa cells by delaying the onset of apoptosis. Suppression of endogenous WNK3 protein by RNA interference accelerates the apoptotic response and promotes the activation of caspase-3. The mechanism of WNK3 action involves interaction with procaspase-3 and heat-shock protein 70. These results demonstrate a role for WNK3 in promoting cell survival and suggest a mechanism at the level of procaspase-3 activation.
Introduction
Programmed cell death or apoptosis can be triggered by extracellular ligands bound to death receptors (extrinsic pathway) or intrinsic signals produced in response to cellular stress or DNA damage (Nicholson and Thornberry, 1997; Orrenius et al., 2003) . Both the extrinsic and intrinsic pathways converge on the activation of caspase-3, an executor protease that directly cleaves specific proteins and thereby inactivates major cellular functions (Igney and Krammer, 2002) . Procaspase-3 is activated through proteolysis by upstream members of the caspase family (Roy et al., 1997) , but little is known about additional regulatory mechanisms. The identification of antiapoptotic factors has been important to understand the regulation of apoptosis and its evasion by tumour cells.
Protein kinases regulate many different cellular responses including apoptosis (Hunter, 2000) and form a superfamily of enzymes containing 518 human genes (Kostich et al., 2002; Manning et al., 2002) . The subfamily of WNK (with no K ¼ lysine) protein kinases has four human members that are characterized by a sequence variation in the catalytic domain (Verı´ssimo and Jordan, 2001) . Most notably, a catalytic lysine residue highly conserved in subdomain II of most other kinases (Hanks and Hunter, 1995) is located in an alternative position in WNK subdomain I (Xu et al., 2000) . WNK kinases are found only in multicellular organisms and the human genome contains four different WNK genes (Verı´ssimo and Jordan, 2001) . Germline mutations in the WNK1 and WNK4 genes were recently found to cause a hereditary form of hypertension, pseudohypoaldosteronism type II (PHAII; Wilson et al., 2001) . WNK4 is expressed in the distal nephron where it appears to regulate paracellular chloride (Cl À ) permeability as well as the traffic of epithelial ion channels such as the sodium-chloride (Na þ -Cl À ) cotransporter and the renal potassium channel ROMK (reviewed in Kahle et al., 2004a; Gamba, 2005) . WNK1 has been found to act as an upstream activator of the extracellular signal-regulated kinase (ERK)5 pathway , to phosphorylate synaptotagmins-2, a protein involved in calciumdependent membrane fusion during exocytosis and endocytosis and to activate the protein kinases SGK1 and SPAK or OSR1 (Moriguchi et al., 2005; Vitari et al., 2005; Gagnon et al., 2006) , which regulate activation of various epithelial ion channels. WNK1 itself is a substrate for protein kinase B upon activation of phosphatidyl inositol-3-kinase (Vitari et al., 2004; Jiang et al., 2005) .
WNK kinases are also expressed in non-renal epithelial tissues (Verı´ssimo and Jordan, 2001; Wilson et al., 2001; Kahle et al., 2004b; Lenertz et al., 2005) , including the still uncharacterized family members WNK2 and WNK3. Although this work was in progress, the genomic organization and expression pattern of the human WNK3 gene have been reported (Holden et al., 2004) ; however, the corresponding WNK3 protein has not been studied. Here, we analysed the human WNK3 protein and describe a role in the negative control of apoptosis.
Results

Cloning and expression of human WNK3
We subcloned the most abundant human WNK3 transcript, which consists of 5232 bp or 1743 amino acids, encoding a protein of 192 kDa calculated molecular weight (GenBank accession number AJ409088; details on alternative splicing are available as Supplemental information, Figure S1 ). In agreement with a recently published analysis of the WNK3 gene (Holden et al., 2004) , we found that the protein kinase catalytic domain of WNK3 is located between residues 147 and 405 ( Figure 1a ) and includes the typical WNK kinase signature motif (Verı´ssimo and Jordan, 2001 ). The catalytic domain of WNK3 is 93% identical to WNK1 and 81% identical to WNK4. The remaining sequence of WNK3 has little homology to other WNK members, except for three small WNK homology regions, namely an acidic motif (residues 537-546) to which hereditary mutations in WNK4 cluster (Wilson et al., 2001) , residues 746-803 without any recognizable motif and residues 1471-1546 including the WNK3 coiled-coil domain (Figure 1a) . WNK3 transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR) in the human cell lines HT29, SW480 (both colon), HeLa (cervix carcinoma) and HEK293 (human embryonic kidney), as well as in Madin-Darby canine kidney cells (canine kidney) (Figure 1b) . Using an antibody raised against a recombinant C-terminal fragment, the corresponding endogenous WNK3 protein was detected in whole lysates from HeLa, SW480 and HEK293 cells as two bands with apparent molecular weights above 250 kDa ( Figure 1c ). The lower band comigrated with transfected Myc-WNK3 and predominates in HEK293 cells, whereas the higher molecular weight band was the Figure 1e ). When endogenous WNK3 was immunoprecipitated from HEK293 cells, catalytic activity towards MBP was also detected (Figure 1f ). These data demonstrate that WNK3 has catalytic protein kinase activity in HEK293 cells.
Localization of endogenous WNK3
The subcellular localization of endogenous WNK3 was determined in HeLa cells. Affinity-purified anti-WNK3 serum revealed a weak, diffuse signal throughout the cell. Interestingly, however, upon the induction of apoptosis, a progressive staining of WNK3 in the cell nucleus was observed by confocal microscopy (see Figure 2 ). This nuclear signal was not observed when cells were previously transfected with WNK3-specific siRNA to downregulate WNK3 expression (data shown in Figure 4b ). This observation prompted us to study in more detail the role of WNK3 in the regulation of apoptosis.
Overexpression of WNK3 increases cell survival HeLa cells were microinjected with expression vectors encoding either green fluorescent protein (GFP)-WNK3, or the inactive GFP-WNK3-K159M mutant, or GFP alone, and then incubated for 6 h to allow expression of the ectopic proteins before apoptosis was induced by the addition of actinomycin D. Cells were fixed after 10-12 h, apoptotic cells labelled by the Tdtmediated dUTP nick-end labelling (TUNEL) assay and the survival of GFP-positive cells counted following fluorescence imaging. The percentage of live cells expressing GFP was 44710%, whereas 5777% survived when cells expressed WNK3-K159M and 7079% were alive upon expression of active WNK3 ( Figure 3a ) (P ¼ 0.007 for GFP vs WNK3). These data indicated that overexpression of WNK3 increases survival of HeLa cells. In order to follow the effect that WNK3 expression has on individual cells, survival was monitored in real time by video time-lapse microscopy. The resulting video movies recorded during 12 h the full progression of apoptosis and allowed to count at subsequent time points the number of dead uninjected and of dead WNK3-injected cells. This time course revealed that in uninjected cells, the number of dead cells increased continuously. In contrast, almost every WNK3-injected cell was alive until 7 h after drug addition (Figure 3b ). This in vivo analysis suggests that at the single-cell level, Figure 2 Nuclear translocation of endogenous WNK3 protein during apoptotic stimulation. HeLa cells were incubated with actinomycin D to induce apoptosis, and then fixed at the indicated time points and endogenous WNK3 protein detected with affinitypurified anti-WNK3 by confocal immunofluorescence microscopy under identical settings of image acquisition. The observed diffuse cellular staining shifted progressively to a signal within the nucleus, as evidenced by confocal sectioning. Bar, 5 mm.
Protein kinase WNK3 increases cell survival F Veríssimo et al the expression of wild-type WNK3 was able to completely block the onset of apoptosis for several hours (Po0.001 in paired Student's t-test). As the stimulus from the apoptotic drug continued, WNK3-injected cells started to die at a similar rate as uninjected cells, and after 9-10 h, the effect of WNK3 expression was overcome.
Suppression of endogenous WNK3 sensitizes cells for apoptosis
In order to investigate the role of WNK3 at physiological protein level, its endogenous expression in HeLa cells was downregulated by RNA interference (RNAi). Then, apoptosis was induced by either etoposide or by actinomycin D and the number of apoptotic cells quantitated by flow cytometry using staining for annexin-V binding as a standard method to detect early apoptotic cells under excluding membrane-damaged necrotic cells (Figure 4a ). In parallel, endogenous Protein kinase WNK3 increases cell survival F Veríssimo et al WNK3 was stained to document successful downregulation (Figure 4b ), estimated by Western blot to reduce WNK3 levels to 50% (see also Figure 6a ). Whereas two control siRNAs had little effect on apoptosis, the inhibition of WNK3 expression increased the number of apoptotic cells 2.5-to three-fold. This increase was observed for apoptosis induction with both actinomycin D (P ¼ 0.05 for siGFP vs siWNK3) and with etoposide (P ¼ 0.008 for siGFP vs siWNK3) ( Figure 4a) .
As an additional technique to interfere with endogenous WNK3, affinity-purified anti-WNK3 antibodies were microinjected into the cytosol of HeLa cells and the remaining live injected cells were counted following induction of apoptosis. Whereas microinjection of buffer alone or a control immunoglobulin G (IgG) antibody slightly decreased cell survival, the presence of anti-WNK3 antibodies clearly reduced the number of viable cells (Figure 4c ) by a factor of 1.65 (P ¼ 0.05 for IgG vs anti-WNK3 (P ¼ 0.017 for buffer vs anti-WNK3).
WNK3 interacts with proteins involved in the regulation of apoptosis
To gain insight into the mechanism by which WNK3 is affecting the apoptotic response, we investigated the interaction of WNK3 with 400 cellular proteins involved in signal transduction using an Antibody Arrayt (www.hypromatrix.com). The array was incubated with an extract from Myc-WNK3-expressing HEK293 cells that was prepared under non-denaturing conditions to preserve protein-protein interactions. Cellular proteins were allowed to bind to their cognate antibodies on the array membrane and Myc-WNK3 interaction then stained by chemiluminescence with an anti-Myc peroxidase conjugate. This approach revealed clear signals above background at the positions of procaspase-3 and heat-shock protein (Hsp)70 (Figure 5a ), two proteins involved in apoptosis.
In order to validate these protein-protein interactions, we co-transfected WNK3 or its kinase-dead mutant, in GFP-tagged versions into HEK293 cells together with vectors encoding the putative binding Protein kinase WNK3 increases cell survival F Veríssimo et al proteins and determined their ability to co-immunoprecipitate. A commercial antiprocaspase-3 antibody was used to precipitate procaspase-3 and the precipitate was found to contain GFP-WNK3 (Figure 5b ). In the case of the binding partner Hsp70, the specific anti-WNK3 antibody immunoprecipitated WNK3 together with YFP-Hsp70 (not shown). This interaction was dependent on the substrate-binding domain (SBD) of Hsp70 because an Hsp70-SBD deletion mutant was unable to interact with WNK3 (Figure 5e ), whereas an Hsp70 ATPase domain point mutant co-immunoprecipitated with WNK3 (Figure 5d ). These interactions were also observed when the kinase-dead WNK3 mutant was tested (Figure 5b-e) .
As negative controls for the specificity of these co-immunoprecipitations, the interaction between GFP-WNK3 and Flag-ERK2 was first tested as ERK2 was one of the antibody array-negative proteins (see Figure 5a ). Anti-Flag antibodies were used to precipitate ERK2, but WNK3 was absent from the precipitate (Figure 5c ). Similarly, anti-WNK3 antibody immunoprecipitated WNK3 but did not pull down Flag-ERK2 (data not shown). Furthermore, procaspase-3 was cotransfected and immunoprecipitated under identical conditions with another WNK member, GFP-WNK4, but no interaction between these two proteins was detected (Figure 5f ).
The prosurvival effect of WNK3 and its interaction with procaspase-3 and Hsp70 suggest a regulatory role in the caspase-dependent apoptotic pathway. In order to provide evidence for an effect on the activation of caspase-3 in vivo, the expression of endogenous WNK3 was first downregulated in HeLa cells by RNAi, then apoptosis induced by etoposide treatment and the number of cells containing active caspase-3 quantitated by flow cytometry. Activation of caspase-3 in untransfected HeLa cells was comparable to the number of positive cells following transfection with two control siRNAs. In contrast, transfection with WNK3-specific siRNA increased by a factor of 2.6, the number of cells in which caspase-3 was activated (P ¼ 0.0002 for siGFP vs siWNK3) (Figure 6b ). Under our experimental conditions, the RNAi resulted in a 50% reduction in endogenous WNK3 (Figure 6a ) and this partial downregulation was sufficient for the observed increase in active caspase-3.
As the expression level of Hsp70 has been reported to influence cell survival, the endogenous Hsp70 protein levels were monitored following the induction of apoptosis in HeLa cells. We found that Hsp70 levels did not change significantly under the experimental conditions (Figure 6c ), suggesting that WNK3 protein levels are responsible for the observed changes in activation of procaspase-3.
Discussion
Previously, we reported the identification of the subfamily of WNK protein kinases in this journal (Verı´ssimo and Jordan, 2001) . Genetic evidence has recently linked the WNK protein kinase subfamily to the molecular pathogenesis of PHAII, a familial disease featuring hypertension. Whereas WNK1 and WNK4 play a role in ion transport pathways in the distal nephron (Kahle et al., 2004a) , nothing was known about the function of the remaining members WNK2 and WNK3. In this work, we have cloned and analysed human WNK3 and found a prosurvival role for the WNK3 protein that involves interaction with procaspase-3. ) were transfected with WNK3-specific or control siRNAs, and 60 h later, apoptosis was induced by adding etoposide. Following 12 h of incubation, cells were labelled with a commercial active caspase-3 antibody apoptosis kit and 6 Â 10 4 cells quantified by flow cytometry. Data were expressed as the relative increase in the number of cells containing active caspase-3 as compared to mocktransfected cells. Note that the increase reflects the effect of a roughly 50% reduction in WNK3 levels, as shown in panel a. (c) Protein levels of endogenous heat-shock protein (Hsp)70 remained unchanged under the experimental conditions used. HeLa cells were treated and apoptosis was induced as above before cells were lysed at the time points indicated. Lysates were analysed by Western blot staining with anti-Hsp70 antibodies and anti-atubulin to demonstrate equal amounts of loaded protein.
Protein kinase WNK3 increases cell survival F Veríssimo et al WNK3 is a large protein with 192 kDa calculated molecular weight and contains a coiled-coil domain. From these characteristics, it can be expected to be involved in multiple protein-protein interactions. We found that WNK3 co-immunoprecipitates with proteins that were previously implicated in the regulation of apoptosis and these interactions occur independent of its kinase activity.
One interacting protein is procaspase-3, whereas all other caspases stained negative on the antibody array. Procaspase-3 exists as an inactive dimer in human cells (Li et al., 1997; Igney and Krammer, 2002; Boatright and Salvesen, 2003) and activation during apoptosis requires proteolytic cleavage through upstream members of the caspase family. This activated caspase-3 cleaves important cellular proteins (Nicholson and Thornberry, 1997) and initiates the execution phase of programmed cell death.
A second WNK3-interacting protein, Hsp70, is known to be involved in multiple protein interactions. Hsps can bind hydrophobic regions in proteins and assist in their folding or in their proteolytic degradation. In addition, specific Hsp70 interactions are known in the disassembly of protein complexes or in the regulated exposure of specific protein domains involved in signal transduction Mayer and Bukau, 2005) . Interestingly, expression of Hsp70 was reported to protect cells against death stimuli (Jaattela and Wissing, 1993; Mosser et al., 1997; Parcellier et al., 2003) . Increased Hsp70 expression in tumours also correlates with evasion from apoptosis (Ciocca et al., 1993; Wei et al., 1995; Jaattela, 1999; Kaur et al., 2000) . Hsp70 was further shown to inhibit the activation of procaspase-3, but not the activity of processed caspase-3 (Mosser et al., 1997; Li et al., 2000; Mosser et al., 2000; Saleh et al., 2000) . Hsp70 was found to associate with Apaf-1 and block the apoptosome-mediated activation of caspase-9, which is an upstream event for caspase-3 activation (Beere et al., 2000; Saleh et al., 2000) . The data presented here indicate that Hsp70 may further operate with WNK3 directly at the level of procaspase-3. This is supported by the previous finding that Hsp70 co-immunoprecipitates with procaspase-3 and -7 and inhibits their activation (Komarova et al., 2004 ). In our experiments described in Figure 5 , we also observed the presence of endogenous Hsp70 when anticaspase-3 antibodies were used to co-immunoprecipitate tagged WNK3 (data not shown). We propose that WNK3 regulates the recruitment of Hsp70 to procaspase-3 because the level of endogenous Hsp70 protein did not change following the induction of apoptosis (Figure 6c ).
Several lines of evidence suggest that WNK3 participates in the regulation of apoptosis. First, endogenous WNK3 progressively accumulates in the nucleus during apoptosis, as evidenced by confocal microscopy ( Figure 2 ). As apoptosis was induced by actinomycin D, a potent inhibitor of RNA polymerase II, the intracellular localization is unlikely to reflect changes in transcription, but rather indicates a redistribution of existing WNK3 protein. This is supported by our observation that transfected WNK3 localizes to the cytosol in HeLa cells (not shown) and that bioinformatic analysis (PSORT II prediction at http://psort.ims.u-tokyo.ac.jp/form2.html) of the WNK3 coding sequence revealed putative nuclear localization motifs.
Second, downregulation of endogenous WNK3 protein levels by RNAi or microinjection of anti-WNK3 antibodies accelerates the apoptotic response to various stimuli. WNK3 physically associates with procaspase-3 and downregulation of WNK3 leads to a statistically significant increase in the number of cells with active caspase-3 (Figure 6b ) -even when only a partial suppression of WNK3 was achieved by RNAi. Third, upon overexpression of wild-type WNK3, the number of apoptotic cells decreases and a microscopic delay in the execution of apoptosis was observed in vivo (Figure 3) .
Endogenous levels of WNK3 are quite low in HeLa cells as judged by Western blot and RT-PCR analysis and when reduced to half by RNAi resulted in a roughly three-fold increase in cell death (Figures 4a and 6b) . The activation of caspases must be tightly controlled in order to prevent inappropriate apoptosis while allowing an effective response to proapoptotic stimuli. Experimental data and mathematical models have suggested that a transition exists from cell survival to cell death, which is controlled by threshold values. This cellular susceptibility value is determined by the relative concentrations of pro-and antiapoptotic factors, as for example, the ratio of Bcl-2 to Bax expression (Danial and Korsmeyer, 2004; Bagci et al., 2006) , or the haploinsufficiency in some factors (Eischen et al., 2004; Gotz et al., 2004) , or the release of subthreshold levels of cytochrome c from the mitochondria that mediate a partial caspase activation insufficient for a full apoptotic response (Cosulich et al., 1999) . Our data indicate that WNK3 participates in the modulation of such apoptotic threshold values. The more moderate protective effect of overexpressing wild-type WNK3 may indicate that further proteins are involved, which interact with or regulate WNK3 and thus rate limit the effect of an increased WNK3 expression in our experimental settings.
The prosurvival role was only in part dependent on the catalytic activity of WNK3 because a kinase-dead WNK3 mutant also interacted with procaspase-3 and increased cell survival to some extent, indicating that the effect of WNK3 is not entirely phosphorylation dependent. Although our in vitro kinase assays have revealed that MBP is a poor substrate for Myc-WNK1 (not shown), immunoprecipitated WNK3 clearly phosphorylated MBP under the same conditions and appears to posses a constitutive level of protein kinase activity in vitro (Figure 1e and f) . Nevertheless, we were not able to detect direct phosphorylation of recombinant procaspase-3 by immunoprecipitated WNK3 in vitro (data not shown). We therefore speculate that WNK3 acts, at least in part, as an adaptor or scaffold protein for a protein complex that controls procaspase-3 activation and negatively regulates activation by sequestering procaspase-3 in a complex. It is actually possible that Hsp70 suppresses the processing of procaspase-3 by binding to its proregion. This mode of action is apparently upstream of that of inhibitor of apoptosis proteins, which act on proteolytically activated caspase-3 (Salvesen and Duckett, 2002) .
Although apoptosis can be triggered by either extracellular signals from death receptors or by intrinsic signals produced in response to cellular stress or DNA damage (Vaux and Strasser, 1996; Orrenius et al., 2003) , both pathways converge on the activation of procaspase-3. Our data indicate that WNK3 has a function in controlling this crucial step and that changes in the level of WNK3 protein levels may determine sensitivity or tolerance of cells towards apoptotic stimuli. Although we found WNK3 is expressed in colorectal tumours, a genome-wide expression analysis did not indicate major changes in WNK3 transcription (S Wiemann, Heidelberg, unpublished data). We observed, however, significant variation in WNK3 protein levels depending on cell density and culture conditions (data not shown) indicating post-transcriptional effects.
Altogether, our findings identify WNK3 as a novel protein involved in the regulation of apoptotic cell death, and suggest that it acts directly at the level of procaspase-3 activation.
Note added
While this manuscript was under revision, a role for WNK3 in the regulation of chloride transporters was reported Rinehart et al., 2005) , which are involved in the maintenance of cell volume in response to osmotic stress. Such osmotic stress has been related to epithelial cell apoptosis in previous reports (Dmitrieva and Burg, 2005) .
Materials and methods
Cell culture and transfections Cells were maintained in Dulbecco's minimal essential medium supplemented with 10% foetal calf serum (GIBCO Invitrogen Corporation, Barcelona, Spain) and regularly checked for the absence of mycoplasm infection. For transfections, cells at 50-90% confluence were transfected using Polyfect (HEK293) or Effectene (HeLa) reagents (Qiagen, Germany), according to the manufacturer's instructions. Transfection efficiencies were 90% for HEK293 and 25% for HeLa. Cells were analysed after 22 or 16 h, respectively. Total amounts of transfected DNA were 4 mg/60-mm dish for biochemical assays and 1 mg per 35-mm dish for immunofluorescence. When required, the amount of DNA was adjusted with empty vector. Expression of endogenous WNK3 in HeLa cells was downregulated by transfection of either siRNAs WNK3-2860 (5 0 -aaaccaagcagccagcuauac-3 0 ) or WNK3-2085 (5 0 -aaaccagauuuaguucgaagc-3 0 ; Dharmacon Research Inc., Lafayette, CO., USA), a scramble siRNA or a GFP-siRNA (Qiagen) as controls, using Oligofectamine (Invitrogen) according to the manufacturer's instructions. After 24 h, cells were trypsinized and replated to avoid confluence. At 60 h post-transfection, cells were analysed as indicated.
cDNA cloning and expression plasmids Based on genomic sequence information, the human WNK3 coding sequence was predicted and then amplified by RT-PCR as expressed in vivo and cloned (see also previous descriptions; Jordan et al., 2000; Verı´ssimo and Jordan, 2001) . Database searches initially revealed the human WNK3 gene on chromosome X in BAC clones RP11-429N14 and RP3-390013 (GenBank accession numbers AL591766 and Z84469, respectively) and the corresponding WNK3 coding sequence was predicted using the GenScan software. Primers were then designed to amplify three overlapping fragments of WNK3 as expressed in vivo, using Pfu turbo polymerase (Stratagene, LaJolla, CA, USA) according to the manufacturer's instructions. The corresponding complementary DNA (DNA) products were subcloned, sequenced and then joined at suitable restriction sites. Fragment 1 (nucleotides (nt) 1-1740) was amplified from human brain Marathon cDNA (Clontech, Mountain View, CA, USA) using primers WNK3-Start-Eco (5 0 -GAATTCTCTGGCGGCGCCGCAGAGAA -3 0 ) and WNK3 Nterm-R (5 0 -CTTGTGCAACATCTTCTGG GACA-3 0 ) in 35 cycles of 931C-60 s, 621C-30 s and 681C-2 min, with an initial denaturation of 2 min at 931C and a final extension of 15 min at 721C. Fragment 2 (nt 1524-5232) was obtained from KIAA clone 1566 (Kazusa Human cDNA Project) following the substitution of the 3 0 -uncoding region by fragment 3. The C-terminal fragment 3 was amplified from KIAA 1566 with primers WNK3-Cterm-F (5 0 -CCGCTTTCT CAAGTTTGACATCGA-3 0 ) and WNK3-Stop-Not (5 0 -GTC TAAGTGGTCCGCAGCGGCCGC-3 0 ). Polymerase chain reaction-amplified fragments were cloned into the Topo-TA vector and sequenced. A PmeI/NotI insert was exchanged between KIAA 1566 and fragment 3, followed by ligation of an EcoRI/Bsu36I insert from fragment 1. WNK3 cDNA was then cloned as an EcoRI/NotI fragment into pcDNA3-Myc. Green fluorescent protein-WNK3 was obtained following a Klenow-fill in reaction of the NotI site to clone into EcoRI and SmaI sites of pEGFP-C1 (Clontech). Kinase-dead point mutations were introduced using the Quick change mutagenesis kit (Stratagene). The nucleotide sequence for the human WNK3 cDNA has been deposited in the GenBank/EBI databank under accession number AJ409088. The human WNK4 cDNA was a gift from X Jeunemaitre (Paris, France) and cloned as an SfiI/NotI fragment together with a synthetic oligo containing the missing 19 N-terminal nucleotides into pcDNA3. From this construct, a KpnI-NotI fragment was cloned into pEGFP-C1 (Clontech). pcDNA3-procaspase-3 (Tewari et al., 1995) , Hsp70-YFP, Hsp70-YFP-SBD mut and Hsp70-YFP-ATPase mut (Kim et al., 2002) , and pCMV-Flag-ERK2 (Moore et al., 2000) were as described. All constructs or fragments were verified by automated DNA sequencing.
Expression studies of WNK3 by RT-PCR Total RNA was extracted from cultured cell lines with the RNAeasy kit (Qiagen), reverse transcribed and amplified using AmpliTaq polymerase (Perkin-Elmer, Wellesley, MA, USA) in 30 cycles of 941C-30 s, 601C-45 s and 721C-1 min, with an initial denaturation of 2 min at 941C and a final extension of 5 min at 721C. Primers for WNK3 were as described (Verı´ssimo and Jordan, 2001) . Representative RT-PCR products were subcloned using the Topo TA-cloning kit (Invitrogen) and five positive colonies sequenced. No amplification was obtained when RNA was mock reverse transcribed without adding reverse transcriptase. The expression profile of human WNK3 kinases splice variants was studied by RT-PCR in various human adult and foetal tissues. Total tissue RNA (kind gift of E Chastre, Paris, France) was reverse transcribed using oligo-dT primers and then amplified with Antibodies A polyclonal antibody was raised against a recombinant WNK3 fragment containing the 230 C-terminal amino acids cloned into the His-tagged pET28 vector. The protein was expressed in the Escherichia coli BL21 strain under isopropylthiogalactosidase induction, extracted from bacterial pellets with 6 M urea, desalted and injected into rabbits according to standard procedures. The serum was affinity-purified from Western blots against the antigen followed by elution of the bound antibodies from the excised polyvinylidine difluoride (PVDF) membrane stripes in 50 mM Na citrate, pH 2.8. The pH was immediately neutralized by addition of 1.5 M Tris-HCl, pH 8.8. Anti-WNK1 was as described (Verı´ssimo and Jordan, 2001) , rabbit anti-CFTR a gift from M Amaral (Lisbon, Portugal), anti-Myc (clone 9E10) and anti-Flag (M2) were from Sigma, anti-GFP (ab290) from AbCam (UK), antiprocaspase-3 (clone 19) from BD-Transduction Laboratories, rabbit antiactive caspase-3 from BD-Pharmingen and antiHsp70 from Amersham Biosciences (Piscataway, NY, USA).
SDS-PAGE and Western blotting
Cells were lysed in sodium dodecyl sulphate (SDS) sample buffer, boiled for 10 min, centrifuged at 2500 g for 30 s and resolved in 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) Protean III minigels (BioRad, Hercules, CA, USA). Proteins were transferred onto PVDF membranes (BioRad) using a Mini Trans-Blot cell (BioRad) at 100 V for 80 min. Membranes were blocked in Tris-buffered saline, 0.1% Tween 20, 2% milk powder, probed using the indicated antibodies and specific binding was detected via a secondary peroxidaseconjugated antibody (BioRad) followed by chemiluminescence. For densitometric estimation of protein quantities, the luminescence films from at least three independent experiments were digitalized and analysed using ImageJ software (NIH).
Immunoprecipitation, antibody array and in vitro kinase assays Human embryonic kidney 293 cells were grown in 60 mm dishes, washed in cold phosphate-buffered saline and lysed on ice in 200 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 130 mM NaCl, 10% glycerol, 10 mM MgCl 2 and 2 Â protease inhibitor cocktail (Sigma)). Total lysates were cleared by centrifugation at 5000 g for 5 min and an 0.1 vol aliquot was added to 5 Â Laemmli sample buffer. The remaining lysate was incubated for 1 h at 41C with specific antibodies pre-coupled to protein G-agarose beads (Roche Applied Science, Indianapolis, IN, USA), and then washed three times in cold lysis buffer. Precipitates were separated by SDS-PAGE and analysed on Western blots with appropriate antibodies to reveal precipitated proteins. In case of the signal transduction antibody array (www.hypromatrix.com), lysates pooled from eight transfected dishes were incubated 2 h at room temperature, washed and complexes containing Myc-WNK3 then directly stained with an anti-Myc peroxidase conjugate. For in vitro protein kinase assays, the beads containing anti-Myc or anti-Flag-precipitated kinases were washed in kinase reaction buffer (30 mM Tris-HCl, pH 8, 20 mM MgCl 2 and 2 mM MnCl 2 ), then incubated in 20 ml kinase reaction buffer at 301C for 30 min in the presence of 25 mCi g-ATP in the presence or absence of 0.75 mg/ml MBP (Upstate Biotechnologies, Charlottesville, VA, USA). All results were confirmed in at least three independent experiments.
Immunofluorescence HeLa cells were grown on coverslips and fixed with 3.7% paraformaldehyde in phosphate-buffered saline (PBS) followed by permeabilization with 0.1% Triton X-100 in PBS. Cells were incubated with an appropriate dilution of the primary antibody for 30 min, washed three times in PBS/0.1% Tween 20 and incubated with the secondary antibodies. Coverslips were mounted on microscope slides with Mowiol and samples examined either on a Zeiss Axiovert 100 fluorescence microscope equipped with a cooled Hamamatsu CCD camera (RGB3-chip) or with a confocal microscope (Zeiss LSM 510). For multichannel imaging, each fluorochrome was imaged sequentially to eliminate cross-talk between the channels. The images were processed in Adobe Photoshop 5.0.
Microinjection
HeLa cells were grown for 1-2 days in 3.5 cm glass bottom dishes (MatTek Corporation, Asland, MA, USA) and then microinjected with GFP-tagged vectors as indicated into cell nuclei using a semiautomated microinjection system (Femtojet, Eppendorf). Microinjections were performed in phenol-free medium containing low carbonate (0.5 g/l) supplemented with penicillin, streptomycin, glutamine and 25 mM HEPES, pH 7.2. Antibodies were co-injected into the cytosol of HeLa cells with 0.03 mg/ml of fluorescein isothiocynate (FITC)-dextran 70 kDa (Sigma) as a microinjection marker. Injected were affinity-purified anti-WNK3 antibody (50 ng/ml), or as controls rabbit IgG (250 ng/ml), or neutralized 50 mM Na citrate buffer, and cells fixed following 12 h of incubation.
Analysis of apoptotic cells
Following microinjection of plasmids encoding GFP-WNK3, its kinase-dead mutant, or GFP alone into HeLa cells as described above, apoptosis was induced by the addition of actinomycin D (200 ng/ml). Following 12 h of incubation, cells were fixed and apoptotic cells identified by TUNEL assay (in situ cell death kit; Roche) according to the manufacturer's instructions. Total numbers of injected cells were 104, 160 and 211 for GFP-WNK3, GFP-WNK3 kinase-dead mutant and GFP, respectively. The mean survival of the 3830 uninjected cells from the individual assays was used to correct for small experimental variations and the percentage of live injected cells was plotted. In case of microinjection of antibodies, the total number of injected cells was 337, 301 and 86 for anti-WNK3, IgG or buffer, respectively. The mean survival of 4145 uninjected cells was used to normalize. When apoptosis was analysed by in vivo imaging of microinjected cells, 200 ng/ml of actinomycin D was added in phenol red-free medium, with 10 mM HEPES (pH 7) after 6 h of expression. Phase-contrast images of live cells were taken every 5 min during 12 h on a Zeiss Axiovert 100 TV microscope equipped with a cooled Hamamatsu CCD camera (ORCA ER) in a pre-incubated 5% CO 2 and 371C chamber. Image acquisition and microscope illumination was controlled by Metamorph software. To identify GFP-transfected cells, an immunofluorescence image was taken at the beginning and end of each phase-contrast images series. The acquired images were loaded into Photoshop software to tag live-transfected and live-untransfected cells with dots of different size. The number of each dot species was then automatically counted as particles using Image J freeware from NIH. Following downregulation of endogenous WNK3, apoptosis was induced by adding either actinomycin D (200 ng/ml) or etoposide (200 ng/ml). Following 12 h of incubation, 1 Â 10 6 cells were either labelled with the FITCconjugated monoclonal active caspase-3 antibody apoptosis kit or the annexin-V R-phycoerythrin-conjugated kit (both Molecular Probes, Leiden, The Netherlands) following the manufacturer's recommendations. In the latter case, necrotic cells were identified by staining for 5 min on ice with 5 mg of 7-amino-actinomycin D (Molecular Probes, Leiden, Netherlands). Stained cells (6 Â 10 4 ) were immediately analysed by flow cytometry in a FACScan 3-colours from Becton Dickinson (Franklin Lakes, NJ, USA). All results were confirmed in at least three independent experiments. Statistical probabilities were calculated in Excel software using unpaired, one-tailed Student's t-tests.
